Aytu BioPharma, Inc. (AYTU) DCF Valuation
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Aytu BioPharma, Inc. (AYTU) Bundle
Explore Aytu BioPharma, Inc. (AYTU) financial potential with our user-friendly DCF Calculator! Enter your projections for growth, margins, and expenses to calculate Aytu BioPharma, Inc. (AYTU) intrinsic value and inform your investment decisions.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 27.6 | 65.6 | 96.7 | 107.4 | 81.0 | 108.1 | 144.3 | 192.5 | 256.9 | 342.9 |
| Revenue Growth, % | 0 | 137.52 | 47.29 | 11.1 | -24.58 | 33.45 | 33.45 | 33.45 | 33.45 | 33.45 |
| EBITDA | -12.2 | -29.0 | -28.0 | -3.5 | -1.0 | -26.3 | -35.2 | -46.9 | -62.6 | -83.6 |
| EBITDA, % | -44.18 | -44.25 | -28.92 | -3.27 | -1.25 | -24.37 | -24.37 | -24.37 | -24.37 | -24.37 |
| Depreciation | 4.6 | 7.7 | 10.1 | 8.8 | 8.3 | 12.4 | 16.5 | 22.0 | 29.4 | 39.3 |
| Depreciation, % | 16.61 | 11.73 | 10.5 | 8.21 | 10.21 | 11.45 | 11.45 | 11.45 | 11.45 | 11.45 |
| EBIT | -16.8 | -36.7 | -38.1 | -12.3 | -9.3 | -38.7 | -51.7 | -69.0 | -92.0 | -122.8 |
| EBIT, % | -60.79 | -55.98 | -39.42 | -11.48 | -11.46 | -35.82 | -35.82 | -35.82 | -35.82 | -35.82 |
| Total Cash | 48.1 | 49.6 | 19.4 | 23.0 | 20.0 | 52.3 | 69.8 | 93.1 | 124.2 | 165.8 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 5.6 | 28.2 | 21.7 | 28.9 | 23.6 | 30.7 | 40.9 | 54.6 | 72.9 | 97.3 |
| Account Receivables, % | 20.39 | 42.93 | 22.46 | 26.94 | 29.16 | 28.38 | 28.38 | 28.38 | 28.38 | 28.38 |
| Inventories | 10.0 | 16.3 | 10.8 | 12.0 | 12.6 | 21.4 | 28.6 | 38.1 | 50.9 | 67.9 |
| Inventories, % | 36.19 | 24.89 | 11.22 | 11.17 | 15.6 | 19.81 | 19.81 | 19.81 | 19.81 | 19.81 |
| Accounts Payable | 11.6 | 19.3 | 11.0 | 13.5 | 10.4 | 23.4 | 31.2 | 41.7 | 55.6 | 74.2 |
| Accounts Payable, % | 42.12 | 29.34 | 11.37 | 12.55 | 12.89 | 21.65 | 21.65 | 21.65 | 21.65 | 21.65 |
| Capital Expenditure | .0 | -2.3 | .0 | .0 | .0 | -.8 | -1.0 | -1.4 | -1.8 | -2.4 |
| Capital Expenditure, % | 0 | -3.57 | 0 | 0 | 0 | -0.71337 | -0.71337 | -0.71337 | -0.71337 | -0.71337 |
| Tax Rate, % | -12.56 | -12.56 | -12.56 | -12.56 | -12.56 | -12.56 | -12.56 | -12.56 | -12.56 | -12.56 |
| EBITAT | -16.8 | -36.9 | -37.6 | -12.3 | -10.5 | -38.6 | -51.5 | -68.8 | -91.8 | -122.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -16.2 | -52.8 | -23.8 | -9.4 | -.5 | -29.9 | -45.6 | -60.9 | -81.3 | -108.5 |
| WACC, % | 22.28 | 22.28 | 22 | 22.28 | 22.28 | 22.22 | 22.22 | 22.22 | 22.22 | 22.22 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -164.6 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -111 | |||||||||
| Terminal Value | -547 | |||||||||
| Present Terminal Value | -201 | |||||||||
| Enterprise Value | -365 | |||||||||
| Net Debt | -5 | |||||||||
| Equity Value | -360 | |||||||||
| Diluted Shares Outstanding, MM | 6 | |||||||||
| Equity Value Per Share | -65.06 |
What You Will Get
- Real Aytu BioPharma Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Aytu BioPharma, Inc. (AYTU).
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates to fit Aytu's specific needs.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Aytu BioPharma’s fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections for Aytu BioPharma, Inc. (AYTU).
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility for Aytu BioPharma, Inc. (AYTU).
Key Features
- Real-Life AYTU Data: Pre-filled with Aytu BioPharma’s historical financials and forward-looking projections.
- Fully Customizable Inputs: Adjust revenue growth, margins, WACC, tax rates, and capital expenditures to suit your analysis.
- Dynamic Valuation Model: Automatic updates to Net Present Value (NPV) and intrinsic value based on your customized inputs.
- Scenario Testing: Create multiple forecast scenarios to explore various valuation outcomes.
- User-Friendly Design: Intuitive, structured layout designed for both professionals and newcomers.
How It Works
- 1. Access the Template: Download and open the Excel file containing Aytu BioPharma, Inc.'s (AYTU) preloaded data.
- 2. Adjust Assumptions: Modify essential inputs such as growth projections, WACC, and capital expenditures.
- 3. Instant Results: The DCF model automatically computes intrinsic value and NPV in real-time.
- 4. Explore Scenarios: Evaluate various forecasts to investigate different valuation results.
- 5. Present with Assurance: Deliver expert valuation insights to reinforce your strategic decisions.
Why Choose Aytu BioPharma Calculator?
- Accuracy: Reliable financial data from Aytu BioPharma ensures precise calculations.
- Flexibility: Tailored for users to easily modify and experiment with various inputs.
- Time-Saving: Eliminate the need to create a financial model from the ground up.
- Professional-Grade: Crafted with the expertise and usability expected at the CFO level.
- User-Friendly: Intuitive interface designed for users of all financial backgrounds.
Who Should Use This Product?
- Healthcare Professionals: Understand the latest developments in biopharmaceuticals and their applications.
- Researchers: Utilize data-driven insights to support studies in drug efficacy and market trends.
- Investors: Evaluate investment opportunities and analyze valuation metrics for Aytu BioPharma, Inc. (AYTU).
- Pharmaceutical Analysts: Enhance your analysis with a comprehensive overview of Aytu's product pipeline.
- Entrepreneurs: Learn from Aytu's strategies in navigating the biopharmaceutical landscape.
What the Template Contains
- Historical Data: Includes Aytu BioPharma’s past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Aytu BioPharma’s intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Aytu BioPharma’s financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.